Ginkgo Bioworks Holdings (DNA) Change in Accured Expenses (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Change in Accured Expenses data on file, last reported at -$11.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 230.8% year-over-year to -$11.6 million; the trailing twelve-month figure through Mar 2026 stood at -$10.1 million (up 76.22% YoY), and the FY2025 full-year result was $10.4 million, up 125.66% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$11.6 million, down from -$6.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $22.1 million in Q3 2025 and bottomed at -$42.0 million in Q3 2024.
• The 5-year median for Change in Accured Expenses is -$818000.0 (2023), against an average of -$3.8 million.
• The widest annual swing landed in 2023, when Change in Accured Expenses soared 178.17%; it then plunged 199814.29% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at -$27.8 million in 2022, then surged by 178.17% to $21.7 million in 2023, then plunged by 143.0% to -$9.3 million in 2024, then gained by 29.17% to -$6.6 million in 2025, then sank by 75.37% to -$11.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$11.6 million (Q1 2026), -$6.6 million (Q4 2025), and $22.1 million (Q3 2025), per Business Quant data.

Peer Comparison